FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 227 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer December 15, 2023 EMA Recommends Extension of Therapeutic Indications for Brentuximab Vedotin June 12, 2025 FDA Approves fam-Trastuzumab Deruxtecan-nxki for HER2-Low Breast Cancer August 24, 2022 Why people and culture matter in research August 10, 2021 Load more HOT NEWS When You Lose a Spouse to Cancer and Need Support Truck Driver Saves People From Bus Fire On Christmas Eve Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms Reunión anual de la American Society of Clinical Oncology de 2023:...
